Brad joined Amgen in 2016 as Director of Discovery Attribute Sciences where he directs a group in ‘Proteomics & Protein Analytics’ at the South San Francisco campus. His proteomics group supports the discovery drug pipeline in protein target expression analysis, basic mechanism of action studies, protein interactions networks, targeted protein degradation, and biomarker discovery and immuno-peptidomics, among other topics. The protein analytics group focuses on protein reagent characterization of complex antibody and protein conjugates.
Brad received his PhD in Chemistry at MIT in 1983 and did a SERC postdoctoral fellowship at Cambridge University where he studied bioactive peptides, protein structure and protein phosphorylation. From 1985 to 2000, Brad was a faculty member in the Department of Pharmaceutical Chemistry at UCSF where he pioneered studies in the structure and function of surface Neisseria and Haemophilus spp. bacterial glyconjugates in infectious diseases, developed protein crosslinking strategies, and continued his studies to advance protein mass spectrometry and emerging proteomic technologies. Before joining Amgen, Brad was a Professor and director of Chemistry at the Buck Institute for Research on Aging where he investigated the basic biology of aging and age-related disease, with a focus on protein posttranslational modifications, protein aggregation, and the remodeling of the cellular proteome in various aging paradigms. In addition, he was a key participant in a large NCI proteomics network (CPTAC) on developing and implementing mass spectrometry-based technologies for blood-based cancer biomarker discovery.
Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, Wiley S, Murphy AN, Gaucher SP, Capaldi RA, Gibson BW, Ghosh SS. Characterization of the human heart mitochondrial proteome. Nat Biotechnol. 2003 Mar; 21(3):281-6. PMID: 12592411
Abbatiello SE, … Gibson BW, Liebler DC, MacCoss MJ, Neubert TA, Paulovich AG, Regnier FE, Tempst P, Carr SA. Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics. 2015 Sep; 14(9):2357-74. PMID: 25693799. https://doi.org/10.1074/mcp.M114.047050
Zawadzka AM, Schilling B, Cusack MP, Sahu AK, Drake P, Fisher SJ, Benz CC, Gibson BW*. Phosphoprotein Secretome of Tumor Cells as a Source of Candidates for Breast Cancer Biomarkers in Plasma. Mol Cell Proteomics. 2014;13(4):1034-49. PMCID: 3977182. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977182/
Rardin MJ, Newman JC, Held JM, Cusack MP, Sorensen DJ, Li B, Schilling B, Mooney SD, Kahn CR, Verdin E, Gibson BW*. Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6601-6. PMID: 23576753. https://doi.org/10.1073/pnas.1302961110
Reis-Rodrigues P, Czerwieniec G, Peters TW, Evani US, Lucanic M, Alavez S, Gaman EA, Vantipalli
M, Mooney SD, Gibson BW*, Lithgow GJ*, Hughes RE*. Proteomic Analysis of Age-dependent Changes in Protein Solubility Identifies Genes that Modulate Lifespan. Aging Cell. 2012;11(1):120 7. PMCID:3437485. https://doi.org/10.1111/j.1474-9726.2011.00765.x
SERC Postdoctoral Fellowship, Cambridge University
Ph.D., Massachusetts Institute of Technology
B.A., Biochemistry & Molecular Biology, University of California- Santa Barbara